Stockscreener 앱 받기
30.81
6.13%
1.78
시간 외 거래:
30.81
전일 마감가:
$29.03
열려 있는:
$29.22
하루 거래량:
887.63K
Relative Volume:
0.84
시가총액:
$1.84B
수익:
-
순이익/손실:
$-103.69M
주가수익비율:
-16.58
EPS:
-1.8579
순현금흐름:
$-70.46M
1주 성능:
+12.49%
1개월 성능:
+12.24%
6개월 성능:
+60.55%
1년 성능:
+46.16%
1일 변동 폭
$28.96
$31.34
1주일 범위
$26.70
$31.75
52주 변동 폭
$13.30
$31.75
Enliven Therapeutics Inc Stock (ELVN) Company Profile
명칭
Enliven Therapeutics Inc
전화
720-647-8519
주소
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
30.81 | 1.74B | 0 | -103.69M | -70.46M | -1.8579 |
VRTX
Vertex Pharmaceuticals Inc
|
451.24 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
736.53 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
681.85 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
306.66 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
143.98 | 29.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-16 | 개시 | Goldman | Buy |
| 2024-12-13 | 개시 | BTIG Research | Buy |
| 2024-09-09 | 개시 | H.C. Wainwright | Buy |
| 2024-06-11 | 개시 | Robert W. Baird | Outperform |
| 2024-04-09 | 개시 | Mizuho | Buy |
| 2023-03-29 | 개시 | Jefferies | Buy |
모두보기
Enliven Therapeutics Inc 주식(ELVN)의 최신 뉴스
Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month HighShould You Buy? - MarketBeat
Enliven Therapeutics stock hits 52-week high at $30.98 By Investing.com - Investing.com Australia
Enliven Therapeutics CMO Collins sells $138,800 in stock - Investing.com
Enliven Therapeutics (ELVN) CMO sells 5,000 shares after option exercise - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Trading 5.3% HigherHere's What Happened - MarketBeat
Enliven Therapeutics stock hits 52-week high at $30.98 - Investing.com
(ELVN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Enliven Therapeutics, Inc. $ELVN Shares Bought by HighVista Strategies LLC - MarketBeat
Energy Moves: Should I trade or invest in Enliven Therapeutics IncEarnings Recap Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Enliven Therapeutics (ELVN) CMO sells 40,000 shares after option exercise - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 10,000 Shares of Stock - MarketBeat
CFO of Enliven (NASDAQ: ELVN) sells 10,000 common shares - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year HighShould You Buy? - MarketBeat
Enliven Therapeutics (ELVN) Form 144: Director sales total 45,000 shares - Stock Titan
Smart Money: Is Enliven Therapeutics Inc a speculative investment2025 Technical Overview & Consistent Income Trade Recommendations - baoquankhu1.vn
TD Asset Management Inc Sells 39,388 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
(ELVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
VIX Spike: Will Enliven Therapeutics Inc benefit from rising consumer demandQuarterly Portfolio Report & Accurate Buy Signal Notifications - baoquankhu1.vn
A Look At Enliven Therapeutics (ELVN) Valuation After Positive ENABLE Trial Progress And Phase 3 Plans - Sahm
Enliven Therapeutics stock hits 52-week high at 30.29 USD - Investing.com Nigeria
Enliven Therapeutics (ELVN) Projected to Post Earnings on Thursday - MarketBeat
Enliven Therapeutics stock hits 52-week high at 30.29 USD By Investing.com - Investing.com Canada
Enliven Therapeutics has cash runway into 2029 - BizWest
Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year HighTime to Buy? - MarketBeat
ELVN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Enliven Therapeutics Q4 Loss Widens - marketscreener.com
Enliven Therapeutics (stock code: ELVN) recently released its financial report for the fourth quarter and full year of fiscal 2025, while also updating the market on the company's latest business developments. - Bitget
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Enliven Therapeutics (NASDAQ: ELVN) advances ELVN-001 toward pivotal CML trial - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) touts ELVN-001 data and $462.6M cash runway - Stock Titan
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - PR Newswire
ELVN: ELVN-001 shows strong efficacy in CML, with pivotal data and phase 3 launch expected in 2024 - TradingView
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - mx.advfn.com
Enliven Therapeutics: Q4 Earnings Insights - Sahm
Head-To-Head Review: ProPhase Labs (NASDAQ:PRPH) & Enliven Therapeutics (NASDAQ:ELVN) - Defense World
ELVN SEC FilingsEnliven Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Lowered by Wall Street Zen - MarketBeat
ELVN Should I Buy - Intellectia AI
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Exploring a 37.94% Upside Potential in Biotech - DirectorsTalk Interviews
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - Finviz
Insider Trends: Can Enliven Therapeutics Inc disrupt its industryJuly 2025 Recap & AI Powered Market Entry Strategies - baoquankhu1.vn
Biotech fireside chat: Enliven Therapeutics at TD Cowen event - Stock Titan
(ELVN) Risk Channels and Responsive Allocation - Stock Traders Daily
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Gem with 58% Upside and Strong Buy Ratings - DirectorsTalk Interviews
Enliven Therapeutics (NASDAQ:ELVN) Director Sells $32,201.40 in Stock - MarketBeat
Heyman, Enliven Therapeutics director, sells $32k in stock By Investing.com - Investing.com Canada
Plan-based 1,230-share sale by Enliven (ELVN) director disclosed - Stock Titan
Investment Report: Is SAIL forming a double bottomInsider Buying & Weekly Momentum Stock Picks - baoquankhu1.vn
Market Catalysts: Is Enliven Therapeutics Inc a speculative investment2025 Institutional Moves & Verified Entry Point Detection - baoquankhu1.vn
Enliven Therapeutics Inc (ELVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.55%
0.19%
자본화:
|
볼륨(24시간):